Next Generation Radiotheranostics Promoting Precision Medicine.

Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-Dotatate for neuroendocrine tumors, and 177Lu-PSMA for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.

Annals of oncology : official journal of the European Society for Medical Oncology. 2023 Mar 14 [Epub ahead of print]

K L Pomykala, B A Hadaschik, O Sartor, S Gillessen, C J Sweeney, T Maughan, M S Hofman, K Herrmann

Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany., Department of Urology, University Hospital Essen, Essen, Germany., School of Medicine, Tulane University, New Orleans, LA, USA., Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Division of Cancer Sciences, University of Manchester, Manchester, UK., Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Oxford Institute for Radiation Oncology, University of Oxford, UK., Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.